The global digital dose inhaler market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 12% during 2021-2026.
Digital dose inhalers are utilized to provide a simple, accurate, and reliable dose counter, which enables asthma and chronic obstructive pulmonary disease (COPD) patients to track adherence to their therapy. These inhalers comprise sensors that record the time of medication administration and provide a low-dose warning indicator. They also offer a large display for easy accessibility and comprehension by varied patient populations. Nowadays, digital dose inhalers are integrated with Bluetooth technology that assists in pairing with a tablet, smartphone, or computer wirelessly to enable the automatic transfer of data.
A considerable rise in the number of individuals diagnosed with chronic respiratory diseases (CRDs), such as bronchial asthma, lung disorders, pulmonary hypertension (PH) and chronic obstructive pulmonary disease (COPD), represents one of the key factors driving the demand for digital dose inhalers worldwide. Additionally, the risk of developing CRDs is increasing around the world on account of the growing number of tobacco smokers, rising levels of air pollution, and occupational dust exposure in the agriculture, forestry, and mining settings. This, in turn, is bolstering the market growth. Apart from this, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are introducing several programs to spread awareness about CRDs and the available treatments. Moreover, dry powder inhaler (DPI) systems are gaining traction as they target the delivery of fine drug particles to the deeper airways in the lungs. As a result, several manufacturers are offering capsule-based and disposable DPI devices with improved reliability, consistency, and cost-effectiveness, which is driving the market. Furthermore, favorable reimbursement policies available to the patients via government-sponsored plans and individual insurance and employee policies are boosting the treatment rates of respiratory disorders. This, in turn, is projected to stimulate the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global digital dose inhaler market report, along with forecasts for growth at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, type and product.
Breakup by Type:
Breakup by Product:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips N.V., Lupin Limited, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG Switzerland and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2020|
|Segment Coverage||Type, Product, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||3M Company, AstraZeneca plc, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, H&T Presspart Manufacturing Ltd., Koninklijke Philips N.V., Lupin Limited, Novartis AG, OPKO Health Inc., Propeller Health (ResMed), Sensirion AG Switzerland and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at